Scenario:
• Endometrioid Adenocarcinoma pT3b pN0 treated with TAH/BSO + XRT
• Phase 1 XRT: 2/10/2024 to 3/13/2024, Whole pelvis XRT IMRT/6x, 180 cGy x 25 fx to 4500 cGy
• Phase 2 XRT: 3/16/2024 to 3/21/2024, Vaginal cuff HDR brachytherapy Ir-192 seeds, 600 cGy x 2 fx to 1200 cGy
Question: How would you code Phase 2 Volume?
• 71 Uterus or Cervix
• 72 Vagina
Answer: 72 Vagina
Rationale & Discussion:
For endometrial or cervical cancers when intracavitary HDR is given after a TAH/BSO, code the primary treatment volume to vagina instead of the organ an origin. This is an exception to the general rules.
Refer to Appendix R: The CTR Guide to Coding Radiation Therapy Treatments in the STORE) Case Study #16